

Chunwan Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/697848/publications.pdf>

Version: 2024-02-01

35
papers

1,663
citations

394286

19
h-index

434063

31
g-index

35
all docs

35
docs citations

35
times ranked

2980
citing authors

#	ARTICLE	IF	CITATIONS
1	The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw283.	3.0	182
2	The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. <i>Oncolimmunology</i> , 2016, 5, e1247135.	2.1	165
3	JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. <i>Oncolimmunology</i> , 2017, 6, e1291106.	2.1	119
4	UFBP1, a Key Component of the Ufm1 Conjugation System, Is Essential for Ufm1-Mediated Regulation of Erythroid Development. <i>PLoS Genetics</i> , 2015, 11, e1005643.	1.5	117
5	H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance. <i>Journal of Immunology</i> , 2015, 195, 1868-1882.	0.4	86
6	Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. , 2019, 7, 157.		85
7	Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. <i>Cancers</i> , 2020, 12, 3379.	1.7	81
8	Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells. <i>Oncotarget</i> , 2016, 7, 83907-83925.	0.8	70
9	IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2018, 201, 264-277.	0.4	69
10	Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis. <i>Cell Reports</i> , 2018, 25, 3036-3046.e6.	2.9	63
11	Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF- α -Dependent Intensification of Oxidative Stress and Tumor Cell Death. <i>Cell Metabolism</i> , 2018, 28, 228-242.e6.	7.2	54
12	Asah2 Represses the p53-Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis. <i>Journal of Immunology</i> , 2021, 206, 1395-1404.	0.4	49
13	The NF- κ B p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription. <i>BMC Cancer</i> , 2015, 15, 770.	1.1	48
14	Autocrine IL6-Mediated Activation of the STAT3-DNMT Axis Silences the TNF- α -RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2020, 80, 3145-3156.	0.4	47
15	Indispensable role of the Ubiquitin-fold modifier 1-specific E3 ligase in maintaining intestinal homeostasis and controlling gut inflammation. <i>Cell Discovery</i> , 2019, 5, 7.	3.1	45
16	CD133+CD24 ^{lo} defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype. <i>Oncotarget</i> , 2016, 7, 78698-78712.	0.8	41
17	SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion. <i>Cancer Immunology Research</i> , 2019, 7, 414-427.	1.6	40
18	Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells. <i>BMC Cancer</i> , 2018, 18, 149.	1.1	36

#	ARTICLE	IF	CITATIONS
19	WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. , 2021, 9, e002624.		36
20	Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy. <i>Molecular Cancer Research</i> , 2019, 17, 420-430.	1.5	34
21	Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression. <i>Cancers</i> , 2021, 13, 1006.	1.7	26
22	MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment. <i>Cellular Immunology</i> , 2021, 360, 104260.	1.4	23
23	SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth. <i>Cancer Letters</i> , 2020, 476, 87-96.	3.2	20
24	Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes. <i>Scientific Reports</i> , 2016, 6, 30816.	1.6	18
25	H3K4me3 mediates the NF- κ B p50 homodimer binding to the <i>pdc1</i> promoter to activate PD-1 transcription in T cells. <i>Oncimmunology</i> , 2018, 7, e1483302.	2.1	15
26	p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy. , 2020, 8, e001365.		12
27	Expression profiles and function of IL6 in polymorphonuclear myeloid-derived suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2233-2245.	2.0	12
28	NF- κ B functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. <i>Oncotarget</i> , 2016, 7, 23395-23415.	0.8	12
29	DDRGG1, a crucial player of ufmylation system, is indispensable for autophagic degradation by regulating lysosomal function. <i>Cell Death and Disease</i> , 2021, 12, 416.	2.7	10
30	G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes. , 2022, 10, e003543.		10
31	H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth. <i>Oncogene</i> , 2022, , .	2.6	10
32	Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. <i>Translational Cancer Research</i> , 2017, 6, S652-S654.	0.4	8
33	Restoring FAS Expression via Lipid-Encapsulated FAS DNA Nanoparticle Delivery Is Sufficient to Suppress Colon Tumor Growth In Vivo. <i>Cancers</i> , 2022, 14, 361.	1.7	8
34	Mutations in HSP70-2 gene change the susceptibility to clinical mastitis in Chinese Holstein. <i>Gene</i> , 2015, 559, 62-72.	1.0	7
35	Gut microbes modulate host response to immune checkpoint inhibitor cancer immunotherapy. <i>Translational Cancer Research</i> , 2018, 7, S608-S610.	0.4	5